Table 1.

Clinicopathologic characteristics of the study population (N = 357).

HCC (N = 214)ICC (N = 122)H-ChC (N = 21)ALL (N = 357)P
Age (mean, range)54 (16–79)59.5 (28–88)58 (37–73)56 (16–88)0.005
Sex (male)190 (88.8%)72 (59.0%)19 (90.5%)281 (78.7%)<0.001
Clinical stage (≥III)71 (33.2%)63 (51.6%)8 (38.1%)142 (39.8%)0.001
Differentiation (moderate)78 (36.4%)37 (30.3%)4 (19%)119 (33.3%)0.3875
HBV±HCV infection168 (78.5%)41 (33.6%)14 (66.7%)223 (62.5%)<0.001
Infestation of liver fluke3 (1.4%)2 (1.6%)05 (1.4%)0.998
Liver cirrhosis196 (91.6%)48 (39.3%)12 (57.1%)256 (71.7%)<0.001
Tissue origins0.15
 Primary199 (93.0%)106 (86.9%)19 (90.5%)324 (90.8%)
 Metastasis15 (7.0%)16 (13.1%)2 (9.5%)33 (9.2%)
 Chemotherapy-naïve188 (87.9%)92 (75.4%)17 (81.0%)297 (83.2%)
Family cancer history0.4759
 Yes75 (35.0%)35 (28.7%)7 (33.3%)117 (32.8%)
 No97 (45.3%)54 (44.3%)8 (38.1%)159 (44.5%)
 Unknown42 (19.6%)33 (27.0%)6 (28.6%)81 (22.7%)
Biliary stone disease78 (36.4%)59 (48.4%)11 (52.4%)148 (41.5%)0.06
  • NOTE: P values indicate the statistical significances of the differences existed in three subtypes.